Publications by authors named "I Catalaa"
Background: Glioblastoma (GBM) systematically recurs after a standard 60 Gy radio-chemotherapy regimen. Since magnetic resonance spectroscopic imaging (MRSI) has been shown to predict the site of relapse, we analyzed the effect of MRSI-guided dose escalation on overall survival (OS) of patients with newly diagnosed GBM.
Methods: In this multicentric prospective phase III trial, patients who had undergone biopsy or surgery for a GBM were randomly assigned to a standard dose (SD) of 60 Gy or a high dose (HD) of 60 Gy with an additional simultaneous integrated boost totaling 72 Gy to MRSI metabolic abnormalities, the tumor bed and residual contrast enhancements.
Purpose: Although perfusion magnetic resonance imaging (MRI) is widely used to identify pseudoprogression, this advanced technique lacks clinical reliability. Our aim was to develop a parameter assessing the hypervascularized fraction of glioblastomas based on volume analysis of dynamic susceptibility contrast-enhanced MRI and evaluate its performance in the diagnosis of pseudoprogression.
Methods: Patients with primary glioblastoma showing lesion progression on the first follow-up MRI after chemoradiotherapy were enrolled retrospectively.
Article Synopsis
- The study aimed to assess the reliability of different methods for calculating cerebral blood volume (CBV) in glioblastomas using DSC-MRI, focusing on inter- and intra-observer variability.
- Twenty-seven untreated glioblastoma patients were analyzed by three observers using both the hotspot method and a volume method involving tumor segmentation, with specific parameters being recalculated two months later.
- Results showed that while the volume method provided good to excellent reproducibility for the maximum and normalized CBV values, the hotspot method demonstrated only fair reproducibility, highlighting that the volume method's parameter %rCBV > 2 could be beneficial for monitoring these tumors over time.
Objective: The purpose of this study was to investigate the possible benefit of repeat surgery on overall survival for patients with recurrent glioblastoma multiforme (GBM).
Methods: We performed a retrospective analysis of data from patients who presented with recurrent GBM over a 5-year period ( = 157), comparing baseline characteristics and survival for patients who had at least 1 new tumor resection followed by chemotherapy (reoperation group, = 59) and those who received medical treatment only (no-reoperation group, = 98) for recurrence.
Results: The baseline characteristics of the two groups differed in terms of WHO performance status (better in the reoperation group), mean age (60 years in the reoperation group vs.
The EP300:BCOR fusion extends the genetic alteration spectrum defining the new tumoral entity of "CNS tumors with BCOR internal tandem duplication".
Acta Neuropathol Commun
November 2020